Yea. Not great to start out telling shareholders we will be hearing something by early August to then in early August say it will be in the coming months. Either way it is clear, with the recent non-clinical data, that they have indeed been looking into ways to get the best results. They just really need to stop overpromising and underdelivering. That can be the previous management's thing but it can't be the new management's thing.
Market Data 
Markets 
AI
